https://mb.cision.com/Public/18595/3556109/88d04748d2757e1a_800x800ar.png
** UCB=E2=80=99s General Meeting of Shareholders 2022
------------------------------------------------------------
=C2=B7 For financial year 2021: Gross dividend of =E2=82=AC 1.30 per share =
(+ 2.36%), payable 3 May 2022
=C2=B7 All agenda items put to vote approved
=C2=B7 The message of Jean-Christophe Tellier, CEO of UCB is available on U=
CB=E2=80=99s global corporate website
Brussels (Belgium), 28 April 2022 =E2=80=93 18:00 (CEST) (regulated informa=
tion) =E2=80=93 Today, UCB held its Annual General Meeting of Shareholders =
(AGM) together with an Extraordinary General Meeting (EGM). The company off=
ered the choice to UCB shareholders to either participate in-person or to c=
ast their vote by proxy and follow the meeting online. At the AGM 147 925 5=
50 shares (77,83% of shares entitled to vote) were represented.=C2=A0
The message of Mr. Jean-Christophe Tellier, Chief Executive Officer of UCB,=
published at the occasion of this general meeting, is available on the UCB=
website (https://www.ucb.com/investors/UCB-shareholders/Shareholders-meeti=
ng-2022) .
During his speech, Mr. Tellier commented: =E2=80=9C2021 was a very strong y=
ear, and 2022 is shaping up into a key transition year =E2=80=A6 Our contin=
ued strong financial performances coupled with impressive clinical mileston=
e achievements and strategic partnerships have provided us the building blo=
cks we need to lead us to our 2025 guidance.=E2=80=9D=C2=A0
Jean-Christophe Tellier also added: =E2=80=9CLooking at UCB today, we have =
built solid foundations, allowing us to focus on the execution of our strat=
egy in the coming years. We are therefore convinced we can live our ambitio=
n and commitment to delivering patient value now and into the future.=E2=80=
=9D
The AGM approved for the fiscal year 2021 the payment of a gross dividend o=
f =E2=82=AC 1.30 per share (net dividend of =E2=82=AC 0.91 per share) compa=
red to =E2=82=AC 1.27 per share for 2020 (net =E2=82=AC 0.889). The ex-divi=
dend date is 29 April 2022, the dividend (coupon no. 25) will be payable as=
of 3 May 2022.
During the AGM, several renewals of members of the Board composition were a=
pproved. The AGM renewed the mandates of Mrs. Kay Davies as independent dir=
ector for a term of 4 years and Mr. Jean-Christophe Tellier and Mr. C=C3=A9=
dric Rijckevorsel as directors for a term of 4 years. Mrs. Kay Davies is ch=
airing the Scientific Committee of the Board and is bringing a unique scien=
tific contribution at the level of the Board.
For the curriculum vitae of the Board members, please visit the UCB website=
: https://www.ucb.com/investors/UCB-governance.=C2=A0
All other agenda items put to vote at the AGM and of the EGM were approved =
by the shareholders. More information including details of the votes will b=
e available soon on the corporate website (https://www.ucb.com/investors/UC=
B-shareholders/Shareholders-meeting-2022) .
The Integrated Annual Report 2021 of UCB can be downloaded on UCB's website=
at https://www.ucb.com/investors/Download-center or is available on the on=
line portal at https://reports.ucb.com/.
The financial results for the first half year 2022 will be published on 28 =
July 2022.=C2=A0
Next year's General Meeting will be held on 27 April 2023.
For further information, contact UCB:=C2=A0
Investor Relations
Antje Witte
Investor Relations, UCB
T +32.2.559.9414
antje.witte@ucb.com=C2=A0
Global Communications=C2=A0
Laurent Schots
Media Relations, UCB
T+32.2.559.9264
Laurent.schots@ucb.com =C2=A0
About UCB=C2=A0
UCB, Brussels, Belgium (www.ucb.com) is a global biopharmaceutical company =
focused on the discovery and development of innovative medicines and soluti=
ons to transform the lives of people living with severe diseases of the imm=
une system or of the central nervous system. With approximately 8 600 peopl=
e in nearly 40 countries, the company generated revenue of =E2=82=AC 5.8 bi=
llion in 2021. UCB is listed on Euronext Brussels (symbol: UCB). Follow us =
on Twitter: @UCB_news
Forward looking statements=C2=A0
This press release may contain forward-looking statements including, withou=
t limitation, statements containing the words =E2=80=9Cbelieves=E2=80=9D, =
=E2=80=9Canticipates=E2=80=9D, =E2=80=9Cexpects=E2=80=9D, =E2=80=9Cintends=
=E2=80=9D, =E2=80=9Cplans=E2=80=9D, =E2=80=9Cseeks=E2=80=9D, =E2=80=9Cestim=
ates=E2=80=9D, =E2=80=9Cmay=E2=80=9D, =E2=80=9Cwill=E2=80=9D, =E2=80=9Ccont=
inue=E2=80=9D and similar expressions. These forward-looking statements are=
based on current plans, estimates and beliefs of management. All statement=
s, other than statements of historical facts, are statements that could be =
deemed forward-looking statements, including estimates of revenues, operati=
ng margins, capital expenditures, cash, other financial information, expect=
ed legal, arbitration, political, regulatory or clinical results or practic=
es and other such estimates and results. By their nature, such forward-look=
ing statements are not guarantees of future performance and are subject to =
known and unknown risks, uncertainties and assumptions which might cause th=
e actual results, financial condition, performance or achievements of UCB, =
or industry results, to differ materially from those that may be expressed =
or implied by such forward-looking statements contained in this press relea=
se. Important factors that could result in such differences include: the gl=
obal spread and impact of COVID-19, changes in general economic, business a=
nd competitive conditions, the inability to obtain necessary regulatory app=
rovals or to obtain them on acceptable terms or within expected timing, cos=
ts associated with research and development, changes in the prospects for p=
roducts in the pipeline or under development by UCB, effects of future judi=
cial decisions or governmental investigations, safety, quality, data integr=
ity or manufacturing issues; potential or actual data security and data pri=
vacy breaches, or disruptions of our information technology systems, produc=
t liability claims, challenges to patent protection for products or product=
candidates, competition from other products including biosimilars, changes=
in laws or regulations, exchange rate fluctuations, changes or uncertainti=
es in tax laws or the administration of such laws, and hiring and retention=
of its employees. There is no guarantee that new product candidates will b=
e discovered or identified in the pipeline, will progress to product approv=
al or that new indications for existing products will be developed and appr=
oved. Movement from concept to commercial product is uncertain; preclinical=
results do not guarantee safety and efficacy of product candidates in huma=
ns. So far, the complexity of the human body cannot be reproduced in comput=
er models, cell culture systems or animal models. The length of the timing =
to complete clinical trials and to get regulatory approval for product mark=
eting has varied in the past and UCB expects similar unpredictability going=
forward. Products or potential products which are the subject of partnersh=
ips, joint ventures or licensing collaborations may be subject to differenc=
es disputes between the partners or may prove to be not as safe, effective =
or commercially successful as UCB may have believed at the start of such pa=
rtnership. UCB=E2=80=99 efforts to acquire other products or companies and =
to integrate the operations of such acquired companies may not be as succes=
sful as UCB may have believed at the moment of acquisition. Also, UCB or ot=
hers could discover safety, side effects or manufacturing problems with its=
products and/or devices after they are marketed. The discovery of signific=
ant problems with a product similar to one of UCB=E2=80=99s products that i=
mplicate an entire class of products may have a material adverse effect on =
sales of the entire class of affected products. Moreover, sales may be impa=
cted by international and domestic trends toward managed care and health ca=
re cost containment, including pricing pressure, political and public scrut=
iny, customer and prescriber patterns or practices, and the reimbursement p=
olicies imposed by third-party payers as well as legislation affecting biop=
harmaceutical pricing and reimbursement activities and outcomes. Finally, a=
breakdown, cyberattack or information security breach could compromise the=
confidentiality, integrity and availability of UCB=E2=80=99s data and syst=
ems.=C2=A0
Given these uncertainties, you should not place undue reliance on any of su=
ch forward-looking statements. There can be no guarantee that the investiga=
tional or approved products potentially described in this press release wil=
l be submitted or approved for sale or for any additional indications or la=
belling in any market, or at any particular time, nor can there be any guar=
antee that such products will be or will continue to be commercially succes=
sful in the future.
UCB is providing this information, including forward-looking statements, on=
ly as of the date of this press release and it does not reflect any potenti=
al impact from the evolving COVID-19 pandemic, unless indicated otherwise. =
UCB is following the worldwide developments diligently to assess the financ=
ial significance of this pandemic to UCB. UCB expressly disclaims any duty =
to update any information contained in this press release, either to confir=
m the actual results or to report or reflect any change in its forward-look=
ing statements with regard thereto or any change in events, conditions or c=
ircumstances on which any such statement is based, unless such statement is=
required pursuant to applicable laws and regulations.=C2=A0
GenericFile
UCB AGM 2022 PR NL (https://mb.cision.com/Public/18595/3556109/903c5e997866=
cd9a.pdf) GenericFile
UCB AGM 2022 PR ENG (https://mb.cision.com/Public/18595/3556109/bd1c5438d85=
9a0ff.pdf) GenericFile
UCB AGM 2022 PR FR (https://mb.cision.com/Public/18595/3556109/89561356290b=
e782.pdf)
______________________
If you would rather not receive future communications from UCB SA, please g=
o to https://eu.vocuspr.com/OptOut.aspx?2973226x20421x103694x1x6868579x2400=
0x6&Email=3Dregnews%40symexglobal.com.
UCB SA, All=C3=A9e de la Recherche, 60 ., Brussels, . B - 1070 Belgium
26/04/2024 20:00
25/04/2024 18:00
25/04/2024 07:01
23/04/2024 20:00
22/04/2024 07:01
19/04/2024 20:00
17/04/2024 07:01
12/04/2024 20:00
12/04/2024 18:01
12/04/2024 07:01